![]() |
市場調查報告書
商品編碼
2178974
人工智慧驅動的數位病理平台市場預測至2034年——全球部署模式、平台組件、人工智慧功能、臨床應用、最終用戶和區域分析AI-Driven Digital Pathology Platforms Market Forecasts to 2034 - Global Analysis By Deployment Mode, Platform Component, AI Functionality, Clinical Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球人工智慧驅動的數位病理平台市場預計將在 2026 年達到 25 億美元,在預測期內以 17.1% 的複合年成長率成長,到 2034 年達到 87 億美元。
人工智慧驅動的數位病理平台整合了人工智慧、全切片成像、數位影像管理和先進的分析技術,以支援組織檢查、疾病檢測、生物標記評估和病理工作流程的自動化。癌症發生率的上升、病理工作量的增加以及對準確快速診斷需求的成長正在推動市場發展。深度學習、計算病理學、雲端影像分析和預測分析的進步正在提升診斷能力。對數位醫療基礎設施、精準腫瘤學和人工智慧驅動的檢測工作流程的投資增加,正在為全球的醫院、診斷實驗室、製藥公司和研究機構創造巨大的商機。
癌症負擔日益加重,對高效數位病理診斷的需求也日益成長。
癌症負擔日益加重,以及對高效數位病理診斷的需求不斷成長,正在推動市場擴張。醫療機構面臨病理工作量增加、診斷複雜性上升以及專業病理醫師短缺的困境。人工智慧驅動的數位病理平台透過輔助自動化組織分析、腫瘤識別、生物標記評分和病例優先排序,幫助提高檢查室效率。全切片成像和數位診斷工作流程的日益普及也促進了其應用。對精準腫瘤學、病理觀察標準化以及更快診斷結果的需求不斷成長,進一步推動了醫療和研究機構對人工智慧驅動的病理解決方案的投資。
數位病理基礎設施高成本,臨床人工智慧檢驗面臨挑戰。
數位病理基礎設施的高成本以及臨床人工智慧檢驗的挑戰正在限制市場成長。實施人工智慧病理系統需要全玻片掃描器、大容量影像儲存、高效能運算以及與實驗室資訊系統 (LIS) 的整合。染色方案、掃描器技術和組織製備方面的差異都會影響演算法效能。臨床檢驗和法規核准流程增加了開發和部署成本。互通性限制和對工作流程變更的抵觸情緒也是其他挑戰。小規模檢查室在從傳統顯微鏡過渡到全數位化病理環境時可能會面臨財務壓力。
擴展人工智慧驅動的生物標記分析和精準腫瘤病理平台
人工智慧驅動的生物標記分析和精準腫瘤病理平台的擴展帶來了巨大的成長機會。先進的計算病理系統能夠量化組織特徵、識別腫瘤模式,並輔助解讀用於標靶癌症治療的生物標記。將病理影像與基因組和臨床資訊整合,可以實現更全面的疾病評估。人工智慧開發商、製藥公司和診斷檢查室之間的夥伴關係正在推動商業化進程。對伴隨診斷、數位病理研究和自動化生物標記評分的投資增加,預計將擴大其在腫瘤學、藥物研發和轉化醫學領域的應用。
演算法偏差、診斷可靠性風險以及不斷變化的監管要求
演算法偏差、診斷可靠性風險以及不斷變化的監管要求威脅著市場擴張。人工智慧病理系統應用於使用不熟悉的掃描儀、染色方法或不同患者群體產生的影像時,可能會產生不一致的結果。誤診和臨床檢驗不足會導致病人安全問題和潛在的法律責任。醫療機構必須解決網路安全、敏感患者資料保護和監管合規性問題。數位病理供應商之間的競爭可能會加劇價格壓力。技術提供者必須展現出強大的臨床性能、透明的檢驗、互通性以及病理學家有效的監督,才能維持市場信心。
新冠疫情凸顯了遠距離診斷協作和靈活體組織切片查室操作的必要性,加速了人們對數位病理學的興趣。醫療機構准入限制促使人們投資於數位切片共用、遠距病理診斷和影像管理平台。然而,設備供應鏈中斷和醫療預算緊張導致一些基礎設施項目延長。隨後,數位病理工作流程的擴展為人工智慧影像分析和自動化診斷支援創造了機會。人們對檢查室韌性、遠距會診和醫療數位化的日益關注,將繼續推動市場發展。
在預測期內,基於雲端的平台細分市場預計將佔據最大佔有率。
由於其可擴展的影像儲存、集中式人工智慧處理以及跨分散式病理網路的可存取性,預計在預測期內,基於雲端的平台細分市場將佔據最大的市場佔有率。雲端基礎設施使醫療機構能夠管理大規模全切片影像資料集並部署高級分析應用程式,而無需維護大規模的本地運算資源。基於訂閱的平台支援靈活的部署和軟體更新。對遠端病理協作和整合檢查室工作流程日益成長的需求正在推動其應用。不斷提高的雲端安全性、資料互通性和人工智慧處理能力進一步鞏固了該細分市場的市場地位。
預計在預測期內,預測病理學和預後分析領域將呈現最高的複合年成長率。
在預測期內,預測病理學和預後分析領域預計將呈現最高的成長率,這主要得益於市場對能夠從數位化組織樣本中提取預後資訊的AI工具的需求不斷成長。先進的模型可以分析組織學模式、腫瘤微環境和組織特徵,從而支持疾病風險評估和治療方案。精準腫瘤學和計算病理學研發投入的增加正在推動該領域的發展。與分子和臨床資料集的整合正在擴展分析能力。診斷檢查室、製藥公司和AI開發商之間更深入的合作有望加速該領域的成長。
在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於其先進的醫療保健基礎設施、對人工智慧的大量投資以及數位病理技術的日益普及。美國正透過其完善的診斷實驗室、大學醫院、製藥公司和醫療技術供應商推動區域發展。對腫瘤診斷和精準醫療日益成長的需求正在促進其應用。完善的研究經費、數位醫療保健基礎設施以及病理人工智慧開發人員與臨床機構之間的合作正在強化商業化進程。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷改進、癌症診斷需求的成長以及對數位病理學投資的持續增加。中國、印度、日本、韓國和澳洲正在推動醫學影像基礎設施建設、檢查室數位化和人工智慧研究。龐大的患者群體和日益成長的病理工作量正在推動自動化診斷解決方案的普及。對醫療技術投資的增加、診斷檢查室網路的擴展以及政府的數位健康舉措都在支持該地區的發展。對高度擴充性的人工智慧病理平台的需求不斷成長,預計將加速市場成長。
According to Stratistics MRC, the Global AI-Driven Digital Pathology Platforms Market is accounted for $2.5 billion in 2026 and is expected to reach $8.7 billion by 2034 growing at a CAGR of 17.1% during the forecast period. AI-Driven Digital Pathology Platforms integrate artificial intelligence, whole-slide imaging, digital image management, and advanced analytical technologies to support tissue examination, disease detection, biomarker assessment, and pathology workflow automation. Increasing cancer prevalence, growing pathology workloads, and demand for accurate and timely diagnoses are driving market expansion. Technological advancements in deep learning, computational pathology, cloud-based image analysis, and predictive analytics are improving diagnostic capabilities. Growing investments in digital healthcare infrastructure, precision oncology, and AI-assisted laboratory workflows are creating significant opportunities across hospitals, diagnostic laboratories, pharmaceutical companies, and research institutions worldwide.
Increasing cancer burden and demand for efficient digital pathology diagnostics
Increasing cancer burden and demand for efficient digital pathology diagnostics are driving market expansion. Healthcare organizations face growing pathology workloads, increasing diagnostic complexity, and shortages of specialized pathologists. AI-driven digital pathology platforms support automated tissue analysis, tumor identification, biomarker scoring, and case prioritization, helping improve laboratory productivity. Growing adoption of whole-slide imaging and digital diagnostic workflows encourages implementation. Increasing demand for precision oncology, standardized pathology interpretation, and faster diagnostic turnaround further strengthens investment in AI-enabled pathology solutions across healthcare and research institutions.
High digital pathology infrastructure costs and challenges in clinical AI validation
High digital pathology infrastructure costs and challenges in clinical AI validation restrain market growth. Implementing AI-enabled pathology systems requires whole-slide scanners, substantial image storage capacity, high-performance computing, and integration with laboratory information systems. Variations in staining protocols, scanner technologies, and tissue preparation can affect algorithm performance. Clinical validation and regulatory approval processes increase development and deployment costs. Limited interoperability and resistance to workflow changes create additional challenges. Smaller laboratories may face financial constraints when transitioning from conventional microscopy to fully digital pathology environments.
Expansion of AI-powered biomarker analysis and precision oncology pathology platforms
Expansion of AI-powered biomarker analysis and precision oncology pathology platforms presents significant growth opportunities. Advanced computational pathology systems can quantify tissue characteristics, identify tumor patterns, and support biomarker interpretation for targeted cancer therapies. Integration of pathology images with genomic and clinical information enables more comprehensive disease assessment. Partnerships between AI developers, pharmaceutical companies, and diagnostic laboratories support commercialization. Increasing investment in companion diagnostics, digital pathology research, and automated biomarker scoring is expected to expand adoption across oncology, drug development, and translational medicine.
Algorithmic bias, diagnostic reliability risks, and evolving regulatory requirements
Algorithmic bias, diagnostic reliability risks, and evolving regulatory requirements threaten market expansion. AI pathology systems may produce inconsistent results when applied to images generated using unfamiliar scanners, staining methods, or patient populations. Diagnostic errors and inadequate clinical validation can create patient safety concerns and potential liability. Healthcare organizations must address cybersecurity, sensitive patient data protection, and regulatory compliance requirements. Increasing competition among digital pathology vendors may create pricing pressure. Technology providers must demonstrate robust clinical performance, transparent validation, interoperability, and effective pathologist oversight to maintain market confidence.
The COVID-19 pandemic accelerated interest in digital pathology by highlighting the need for remote diagnostic collaboration and flexible laboratory operations. Restrictions on physical access to healthcare facilities encouraged investment in digital slide sharing, remote pathology review, and image management platforms. However, equipment supply chain disruptions and healthcare budget pressures delayed certain infrastructure projects. The subsequent expansion of digital pathology workflows has created opportunities for AI-assisted image analysis and automated diagnostic support. Growing emphasis on laboratory resilience, remote consultation, and healthcare digitalization continues to support market development.
The cloud-based platforms segment is expected to be the largest during the forecast period
The cloud-based platforms segment is expected to account for the largest market share during the forecast period due to scalable image storage, centralized AI processing, and accessibility across distributed pathology networks. Cloud infrastructure enables healthcare organizations to manage large whole-slide image datasets and deploy advanced analytical applications without maintaining extensive local computing resources. Subscription-based platforms support flexible implementation and software updates. Increasing demand for remote pathology collaboration and integrated laboratory workflows encourages adoption. Improvements in cloud security, data interoperability, and AI processing capabilities further strengthen the segment's market position.
The predictive pathology & prognostic analytics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the predictive pathology & prognostic analytics segment is predicted to witness the highest growth rate due to increasing demand for AI tools capable of extracting prognostic insights from digitized tissue samples. Advanced models can analyze histological patterns, tumor microenvironments, and tissue characteristics to support disease risk assessment and treatment planning. Growing investment in precision oncology and computational pathology research encourages development. Integration with molecular and clinical datasets is expanding analytical capabilities. Increasing collaboration between diagnostic laboratories, pharmaceutical companies, and AI developers is expected to accelerate segment growth.
During the forecast period, the North America is expected to hold the largest market share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and growing adoption of digital pathology technologies. The United States leads regional development through established diagnostic laboratories, academic medical centers, pharmaceutical companies, and healthcare technology providers. Increasing demand for oncology diagnostics and precision medicine supports implementation. Established research funding, digital healthcare infrastructure, and collaborations between pathology AI developers and clinical institutions strengthen commercialization.
Over the forecast period, the Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing cancer diagnostic demand, and growing investment in digital pathology. China, India, Japan, South Korea, and Australia are advancing medical imaging infrastructure, laboratory digitalization, and artificial intelligence research. Large patient populations and increasing pathology workloads encourage adoption of automated diagnostic solutions. Growing healthcare technology investment, expanding diagnostic laboratory networks, and government digital health initiatives support regional development. Increasing demand for scalable AI-powered pathology platforms is expected to accelerate market growth.
Key players in the market
Some of the key players in the AI-Driven Digital Pathology Platforms Market include PathAI, Inc., Proscia Inc., Ibex Medical Analytics Ltd., Aiforia Technologies Plc, Visiopharm A/S, Indica Labs, Inc., Mindpeak GmbH, Qritive, Owkin, Inc., Nucleai, Inc., Techcyte, Inc., Deep Bio Inc., Tempus AI, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Leica Biosystems, Hamamatsu Photonics K.K., and Sectra AB.
In October 2026, Agilent Technologies announced a definitive agreement to acquire Proscia Inc., a provider of enterprise digital pathology software, for $240 million in cash at closing and up to an additional $30 million in performance-based payments. The proposed acquisition is intended to strengthen Agilent's pathology portfolio by integrating digital image management and AI-enabled software with its existing laboratory technologies.
In October 2026, Aiforia Technologies Plc announced a commercial collaboration with PathAI, Inc. to expand access to AI-powered pathology diagnostics through PathAI's AISight Marketplace. The agreement enables laboratories using PathAI's digital pathology image management platform to access Aiforia's AI applications within established case review workflows.
In September 2026, Proscia Inc. announced that Unilabs was deploying its Concentriq digital pathology platform across multiple European markets. The initiative connects pathologists, diagnostic workflows, digital slides, and AI capabilities within an enterprise environment. Several Unilabs operations had already implemented Concentriq AP-Dx for routine case review, with additional deployments planned.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.